ArticleRadiologie (Heidelberg, Germany)2025
[Pulmonary involvement in rare systemic diseases-part 2 : Pulmonary manifestations in the context of lysosomal and metabolic storage diseases, phacomatosis, and neuromuscular disorders].
Article in Radiologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary manifestations of systemic diseases represent a complex and diagnostically challenging field. While pulmonary involvement in immunological and hematological disorders is well described, lung involvement in rare genetic and congenital systemic diseases-such as systemic storage diseases, neuromuscular disorders, and phacomatoses-is only gradually gaining increased attention in radiological diagnostics.
resultsThe pulmonary component often manifests secondarily, frequently after years of progression and worsening of the underlying disease. Early detection of pulmonary manifestations is crucial for therapeutic management and the overall disease outcome. In imaging, high-resolution computed tomography (HRCT) plays a key role. As a technological innovation, photon-counting detector CT (PCD-CT) offers new diagnostic opportunities by providing significantly improved spatial resolution and an optimized signal-to-noise ratio compared to state-of-the-art energy-integrating detector CT (EID-CT) systems.
conclusionThe targeted application of these advanced CT technologies can thus not only improve the differential diagnostic classification of pulmonary manifestations but also enable timely therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.